Lurasidone Low-Dose - High-Dose Study Study

NCT01821378 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

412

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Lurasidone
DRUG: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
DRUG: Placebo

Sponsor

Sumitomo Pharma America, Inc.